As women navigate perimenopause, changes in hormone levels can influence various aspects of health, including insulin sensitivity. Insulin resistance, a condition where the body’s cells don’t respond effectively to insulin, can become more common during this time. Managing insulin sensitivity is a key consideration for overall well-being in midlife.
This article explores two compounds often discussed in relation to insulin sensitivity: inositol (specifically myo-inositol and D-chiro-inositol) and metformin. While much of the existing research on these agents focuses on women with Polycystic Ovary Syndrome (PCOS), understanding their mechanisms and available evidence can offer valuable insights for women in perimenopause considering their options.
Understanding Insulin Resistance in Midlife
Insulin resistance means that the body needs to produce more insulin to maintain normal blood glucose levels. Over time, this can lead to elevated insulin and glucose levels. While perimenopause itself doesn’t directly cause insulin resistance, hormonal shifts, particularly fluctuating and declining estrogen levels, can impact how the body processes glucose and responds to insulin.
Lifestyle factors, including diet, physical activity, and stress, also play significant roles in the development and management of insulin sensitivity. For women experiencing perimenopausal changes, addressing insulin resistance can contribute to better metabolic health and overall comfort during this transition.
Inositol: A Natural Compound for Metabolic Support
Inositol, particularly myo-inositol and D-chiro-inositol, are naturally occurring compounds that play a role in cell signaling and insulin pathways. They are often referred to as ‘insulin sensitizers’ because they may help improve the body’s response to insulin.
Research, largely in the context of PCOS, suggests that inositol can have beneficial effects on metabolic markers. A systematic review and meta-analysis confirmed that inositol is an effective and safe option in PCOS [1]. Another review noted that myo-inositol, alone or with folic acid, has shown positive results in managing PCOS [2]. These findings highlight inositol’s potential to support insulin sensitivity.
Metformin: A Common Medication for Insulin Sensitivity
Metformin is a medication commonly prescribed to help manage insulin resistance, particularly in conditions like type 2 diabetes and PCOS. It works by reducing glucose production by the liver and improving the body’s sensitivity to insulin. Metformin has been extensively studied, and its efficacy in improving metabolic profiles in women with PCOS is well-established [3].
A Cochrane review also recognized metformin as an insulin-sensitizing drug for women with PCOS, oligo-amenorrhea, and subfertility, noting its role in addressing these aspects [4]. Its long history of use provides a substantial body of evidence regarding its effects.
Inositol vs. Metformin: Comparative Evidence
When comparing inositol and metformin, much of the direct evidence comes from studies in women with PCOS. A study comparing myo-inositol and metformin in women with PCOS found both to be effective insulin sensitizers, suggesting comparable benefits in certain aspects [5]. This indicates that inositol may offer similar support to metformin in improving insulin sensitivity in this population.
A network meta-analysis that compared various insulin sensitizers, including metformin and inositol, in women with PCOS, further explored their relative effectiveness in improving endocrine and metabolic profiles [3]. This type of analysis helps to synthesize findings across multiple studies, providing a broader perspective on comparative efficacy.
Recent research, including a systematic review and meta-analysis to inform the 2023 update of international evidence-based PCOS guidelines, reinforces inositol’s role in PCOS management [6]. While direct comparative studies specifically in perimenopausal women are limited, the robust evidence from PCOS populations offers a foundation for understanding their potential benefits related to insulin sensitivity.
Inositol and Metformin Together: Combination Approaches
Some research has also explored the effects of combining inositol with metformin. A systematic review and meta-analysis examined the comparison of metformin with inositol versus metformin alone in women with PCOS. The findings indicated that the combination might offer additional advantages over metformin alone in certain outcomes [7].
Another randomized controlled trial compared metformin plus myoinositol versus metformin alone in PCOS women undergoing ovulation induction cycles. This study also suggested potential benefits of the combination approach [8]. These studies suggest that for some individuals, a combined approach might be considered, potentially offering enhanced support for insulin sensitivity and related metabolic markers.
References
- Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive biology and endocrinology : RB&E, 2023
- Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Hormone molecular biology and clinical investigation, 2018
- Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reproductive health, 2021
- Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. The Cochrane database of systematic reviews, 2017
- Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2017
- Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of clinical endocrinology and metabolism, 2024
- Comparison of metformin with inositol versus metformin alone in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Endocrine, 2025
- Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2019
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
